左右侧结肠癌差异研究进展  

Research Progress on the Difference between Left and Right Colon Cancer

作　　者：翟丁莹 刘勇峰[1] 

机构地区：[1]延安大学附属医院,陕西 延安

出　　处：《临床医学进展》2022年第7期5999-6006,共8页Advances in Clinical Medicine

摘　　要：结肠癌不是一个单一的疾病。因组织胚胎发育、肠道免疫及大肠菌群分布的差异性,左侧结肠癌和右侧结肠癌可能具有不同的生物学行为。在转移性结肠癌的辅助治疗中,左侧RAS野生型结肠癌使用抗EGFR单克隆抗体加化疗比较合理,右侧RAS野生型结肠癌的一线治疗方案可选择化疗加贝伐珠单抗。作者对左右侧结肠癌差异研究进展进行了综述。Colon cancer is not a single disease. Due to differences in tissue embryonic development, intestinal immunity and distribution of coliforms, left colon cancer and right colon cancer may have different biological behaviors. In the adjuvant treatment of metastatic colon cancer, it is reasonable to use anti-EGFR monoclonal antibody plus chemotherapy for left RAS wild-type colon cancer, and chemo-therapy plus bevacizumab is the first-line treatment option for right RAS wild-type colon cancer. The author reviewed the research progress of the difference between left and right colon cancer.

关 键 词：结肠癌 侧边性 免疫 靶向 治疗 

分 类 号：R735.35[医药卫生—肿瘤]